Biogen Inc [BIIB] stock prices are up 0.86% to $130.55 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BIIB shares have gain 6.00% over the last week, with a monthly amount glided 12.07%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Biogen Inc [NASDAQ: BIIB] stock has seen the most recent analyst activity on April 28, 2025, when HSBC Securities downgraded its rating to a Hold but kept the price target unchanged to $118 for it. Previously, Argus downgraded its rating to Hold on April 04, 2025. On February 11, 2025, Bernstein initiated with a Mkt Perform rating and assigned a price target of $160 on the stock. Piper Sandler downgraded its rating to a Neutral and decreased its price target to $138 on January 02, 2025. BMO Capital Markets downgraded its rating to a Market Perform and reduced its price target to $164 on December 20, 2024. Stifel downgraded its rating to Hold for this stock on December 16, 2024, but kept the price target unchanged to $175.
The stock price of Biogen Inc [BIIB] has been fluctuating between $110.04 and $238.00 over the past year. Currently, Wall Street analysts expect the stock to reach $193.75 within the next 12 months. Biogen Inc [NASDAQ: BIIB] shares were valued at $130.55 at the most recent close of the market. An investor can expect a potential return of 48.41% based on the average BIIB price forecast.
Analyzing the BIIB fundamentals
The Biogen Inc [NASDAQ:BIIB] reported sales of 9.40B for trailing twelve months, representing a surge of 6.17%. Gross Profit Margin for this corporation currently stands at 0.8% with Operating Profit Margin at 0.31%, Pretax Profit Margin comes in at 0.18%, and Net Profit Margin reading is 0.15%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.09 and Total Capital is 0.13. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.39.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Biogen Inc [NASDAQ:BIIB]’s Current Ratio is 1.44. Also, the Quick Ratio is 1.01, while the Cash Ratio stands at 0.49. Considering the valuation of this stock, the price to sales ratio is 2.03, the price to book ratio is 1.13 and price to earnings (TTM) ratio is 12.89.
Transactions by insiders
Recent insider trading involved Singhal Priya, Head of Development, that happened on May 19 ’25 when 3806.0 shares were sold. Officer, Singhal Priya completed a deal on May 19 ’25 to buy 3806.0 shares. Meanwhile, Director DORSA CAROLINE bought 1235.0 shares on May 02 ’25.
